



## Background

- Sickle cell disease (SCD) is a lifelong hemoglobinopathy associated with serious health complications, including pain crises and stroke.
- The Michigan Sickle Cell Data Collection (MiSCDC) program is a CDC-funded, population-based surveillance system led by MDHHS and the CHEAR Center at the University of Michigan.
- MiSCDC combines data from multiple sources to understand population trends and healthcare utilization of persons living with SCD in Michigan.

## Objective

The objective is to describe the prevalence, demographics, healthcare utilization, and mortality of people living with SCD in Michigan.

## Methods

- MiSCDC data were acquired for the most recent complete year available (2020) and were linked and deduplicated on a person-level using Linkage Wiz, a probabilistic data matching tool (Table 1).


Table 1: MiSCDC data sources that were linked and deduplicated (2020)

| Data Source                            | Populations Included  |
|--|---|
| Vital Records                          | Births and deaths   |
| SCD Clinics                            | Individuals receiving SCD-related care at clinic  |
| Children's Special Healthcare Services | Children with special healthcare needs covered under Title V funding                          |
| Michigan Medicaid                      | All individuals enrolled in Medicaid  |
| Hospital Discharge                     | Anyone with emergency department, outpatient, or inpatient encounters in Michigan (all-payer) |
| Newborn Screening                      | All infants screened in Michigan since October 1987   |

- Validated case definitions were used to identify confirmed (newborn screening result or clinical confirmation) and probable (3+ administrative claims for SCD across a 5-year period) cases of SCD living in the state in 2020.
- Demographics were obtained from all data sources and prioritized based on an established data hierarchy.
- Number and length of inpatient admissions, number of emergency department (ED) visits, and county of residence were obtained from administrative claims.
- Mortality in 2020 was assessed using vital records for all individuals with SCD ever living in Michigan.

## Results

Figure 1: Inpatient Admission and ED Visit Utilization by Age, 2020 (4,010 persons; 4,271 inpatient admissions; 9,560 ED visits)



### Prevalence and Demographics

- We identified 4,010 total persons (58% female) living in Michigan in 2020.
- The average age was 30 years (standard deviation (SD)=19).
- Most persons (63%) resided in southeast Michigan, which includes metro Detroit.


### Inpatient Utilization

- In 2020, people with SCD had an average of 1.1 inpatient admissions (SD=3) with an overall average length of stay (LOS) of 7 days (SD=21); Figure 1 details inpatient admissions by age, and Figure 2 details total inpatient days and average LOS by age.
- Inpatient admissions were initiated in the ED 73% of the time and 51% of inpatient admissions occurred within 30 days of another inpatient admission or ED visit.
- Inpatient utilization was reduced in 2020 compared to 2019 (total admissions=4,992 among 3,987 persons; overall mean per person=1.3; overall mean LOS=8.0) for all age groups; although reduced overall, total inpatient days increased for those 30-39 years old in 2020 compared to 2019 (inpatient days=7,922).
- Initiation in ED and 30-day readmissions were similar for both years.

### Emergency Department (ED) Utilization

- On average, people with SCD had 2.4 ED visits in 2020 (SD=9); Figure 1 details ED visits by age.
- 68% of ED visits occurred within 30 days of another inpatient admission or ED visit.

Figure 2: Total Inpatient Days and Average Length of Stay (LOS), 2020 (4,010 persons; 29,675 inpatient days)



### Emergency Department (ED) Utilization Ctd.

- ED utilization was reduced in 2020 compared to 2019 (total ED visits=11,396 among 3,987 persons; overall mean per person=2.9) for all age groups except for those 60+ years old.

### Mortality

- There were 98 deaths in 2020; the average age at death was 51 years (SD=19).
- The number of deaths in 2020 is approximately 1.5 times greater than 2019, likely due to the COVID-19 pandemic.

## Conclusions

- MiSCDC can track trends in the epidemiology and healthcare utilization of people living with SCD in Michigan using linked data sources.
- These findings can be applied to understand the impacts of COVID-19 on this population as well as evaluate disease burden and identify policy targets aimed at improving the quality of life for persons living with SCD.

